We hypothesized that HIPEC, with the use of gemcitabine after cytoreductive surgery, will decrease tumor progression of pancreatic cancer by reducing the residual neoplastic volume and PaCSCs subpopulation (EpCAM+CXCR4+CD133+), improving patient survival by reducing disease recurrence. The gene discussed is CXCR4; the disease is pancreatic neoplasm.